- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Century Therapeutics Inc (IPSC)
Century Therapeutics Inc stock price live, this page displays NASDAQ IPSC stock exchange data. View the IPSC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Century Therapeutics Inc real time stock price chart below.
What Is the Century Therapeutics Inc Stock Price Today?
The Century Therapeutics Inc stock price today is 0.558.
What Is the Stock Symbol for Century Therapeutics Inc?
The stock symbol for Century Therapeutics Inc is ""IPSC.""
What Stock Exchange Does Century Therapeutics Inc Trade On?
Century Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Century Therapeutics Inc a Good Stock to Buy?
Determining whether Century Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPSC quote. (ISIN: US15673T1007)
What Is the Century Therapeutics Inc Stock Price Today?
The Century Therapeutics Inc stock price today is 0.558.
What Is the Stock Symbol for Century Therapeutics Inc?
The stock symbol for Century Therapeutics Inc is ""IPSC.""
What Stock Exchange Does Century Therapeutics Inc Trade On?
Century Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Century Therapeutics Inc a Good Stock to Buy?
Determining whether Century Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPSC quote. (ISIN: US15673T1007)
NASDAQ
Currency in USD
0.558
+0.008(+1.40%)
Real-time Data·
Fair Value
An estimate of a Century Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.550
0.580
52 wk Range
0.342
2.050
IPSC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IPSC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Century Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.5500.580
52 wk Range
0.3422.050
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IPSC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Century Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
4.250
Upside
+661.65%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Century Therapeutics Inc Company Profile
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Compare IPSC to Peers and Sector
Metrics to compare | IPSC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPSCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −2.3x | −0.5x | |
PEG Ratio | −0.02 | −0.09 | 0.00 | |
Price/Book | 0.2x | 1.1x | 2.6x | |
Price / LTM Sales | 0.4x | 7.0x | 3.3x | |
Upside (Analyst Target) | - | 309.8% | 40.6% | |
Fair Value Upside | Unlock | 15.2% | 5.3% | Unlock |
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.250
(+661.65% Upside)
Earnings
Latest Release
Aug 14, 2025
EPS / Forecast
-0.38 / -0.38
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Century Therapeutics Trade On?
Century Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Century Therapeutics?
The stock symbol for Century Therapeutics is "IPSC."
What Is the Century Therapeutics Market Cap?
As of today, Century Therapeutics market cap is 49.28M.
What Is Century Therapeutics's Earnings Per Share (TTM)?
The Century Therapeutics EPS (TTM) is -0.26.
When Is the Next Century Therapeutics Earnings Date?
Century Therapeutics will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is IPSC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Century Therapeutics Stock Split?
Century Therapeutics has split 0 times.
How Many Employees Does Century Therapeutics Have?
Century Therapeutics has 145 employees.
What is the current trading status of Century Therapeutics (IPSC)?
As of 15 Aug 2025, Century Therapeutics (IPSC) is trading at a price of 0.56, with a previous close of 0.55. The stock has fluctuated within a day range of 0.55 to 0.58, while its 52-week range spans from 0.34 to 2.05.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.